Study types
- article 14
- other 1
Condition tags
- endometriosis 15
- chronic_pelvic_pain 4
- dysmenorrhea 1
- dyspareunia 1
Top journals
Frequent coauthors
Endometriosis affects reproductive-aged females and varies considerably in terms of symptom presentation, morphologic features, and treatment response. Most studies investigating symptom recurrence after an endometriosis-related surgery hav…
We described trends in pelvic pain characteristics over 2 years of follow-up among adolescents and adults with and without endometriosis participating in the longitudinal observational cohort of the Women's Health Study: From Adolescence to…
OBJECTIVE: To estimate the efficacy and safety of a novel nonhormonal therapeutic agent, cabergoline, compared with that of the standard clinical therapy, norethindrone acetate (NETA), for the treatment of endometriosis-associated pain in y…
Study objectiveTo explore the potential occurrence of long-term side effects and tolerability of gonadotropin-releasing hormone agonist (GnRHa) plus 2 different add-back regimens in adolescent patients with endometriosis.DesignFollow-up que…
PurposeWhile endometriosis is recognized to have a high patient burden for adults, the level of morbidity it causes for adolescents has been understudied, and may be minimized by clinicians. The purpose of this study was to determine whethe…
Study objectiveUse of gonadotropin-releasing hormone agonists (GnRHa) to treat endometriosis can cause mood and vasomotor side effects. "Add-back therapy," the combination of low-dose hormones, limits side effects but research is limited to…
OBJECTIVE: To assess whether add-back therapy with norethindrone acetate or norethindrone acetate plus conjugated equine estrogens is superior to maintain bone health in adolescents and young women using gonadotropin-releasing hormone agoni…
Endometriosis often begins during adolescence. Appropriate management includes prompt initiation of therapy and long-term maintenance therapy. Gonadotropin-releasing hormone (GnRH) agonists are commonly used second-line therapy for patients…